Pay-for-performance program changes cancer prescribing but not costs
- PDF / 185,584 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 63 Downloads / 226 Views
PharmacoEconomics & Outcomes News 864, p24 - 17 Oct 2020 Pay-for-performance program changes cancer prescribing but not costs A commercial health insurer’s pay-for-performance (P4P) program changes cancer drug prescribing but has no impact on total healthcare expenditure, according to findings of a US differences-in-differences study published in the Journal of Clinical Oncology. Anthem administrative claims data for 25 042 patients with cancer and 1867 oncologists in 14 US states were used to evaluate the impact of the roll-out of Cancer Care Quality Program (CCQP) P4P program between 2014 and 2015 on prescribing of evidence-based cancer drugs, drug expenditure, out-of-pocket (OOP) costs and total healthcare spending over a 6-month period after the index claim in adults with breast, lung or colon cancer. In adjusted analysis, the P4P program was estimated to increase evidence-based prescribing by 5.1 percentage points, from 57.1% to 62.2% (p
Data Loading...
